Skip to Content
Merck
  • Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.

Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.

The Journal of pharmacology and experimental therapeutics (2014-09-06)
Chunhua Jin, Yejoo Jeon, Daniel T Kleven, Jennifer S Pollock, John J White, David M Pollock
ABSTRACT

Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared with either treatment alone. Male Dahl salt-sensitive rats were fed a high-fat (36% fat), high-salt (4% NaCl) diet for 4 weeks. Separate groups of rats were then treated with vehicle (control), ABT-627 (ABT; 5 mg/kg per day, in drinking water), chlorthalidone (CLTD; 5 mg/kg per day, in drinking water), or both ABT plus CLTD. Mean arterial pressure (MAP) was recorded continuously by telemetry. After 4 weeks, both ABT and CLTD severely attenuated the development of hypertension, whereas the combination further reduced MAP compared with ABT alone. All treatments prevented proteinuria. CLTD and ABT plus CLTD significantly reduced nephrin (a podocyte injury marker) and kidney injury molecule-1 (a tubulointerstitial injury marker) excretion. ABT, with or without CLTD, significantly reduced plasma 8-oxo-2'-deoxyguanosine, a measure of DNA oxidation, whereas CLTD alone had no effect. All treatments suppressed the number of ED1(+) cells (macrophages) in the kidney. Plasma tumor necrosis factor receptors 1 and 2 were reduced only in the combined ABT and CLTD group. These results suggest that ABT and CLTD have antihypertensive and renal-protective effects in a model of metabolic syndrome that are maximally effective when both drugs are administered together. The findings support the hypothesis that combined ETA antagonist and diuretic treatment may provide therapeutic benefit for individuals with metabolic syndrome consuming a Western diet.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
8-Hydroxy-2′-deoxyguanosine, ≥98% (TLC)
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Cholesterol, from sheep wool, ≥92.5% (GC), powder
SKU
Pack Size
Availability
Price
Quantity
Supelco
Cholesterol, Pharmaceutical Secondary Standard; Certified Reference Material
SKU
Pack Size
Availability
Price
Quantity
USP
Chlorthalidone, United States Pharmacopeia (USP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Chlorthalidone, European Pharmacopoeia (EP) Reference Standard
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Cholesterol, Sigma Grade, ≥99%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Cholesterol, tested according to Ph. Eur.
SKU
Pack Size
Availability
Price
Quantity
Supelco
Cholesterol solution, certified reference material, 10 mg/mL in chloroform
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
SyntheChol® NS0 Supplement, 500 ×, synthetic cholesterol, animal component-free, aqueous solution, sterile-filtered, suitable for cell culture
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Cholesterol, powder, BioReagent, suitable for cell culture, ≥99%
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Chlorthalidone, ≥98% (HPLC)
SKU
Pack Size
Availability
Price
Quantity
SAFC
Cholesterol, from sheep wool, Controlled origin, meets USP/NF testing specifications
SKU
Pack Size
Availability
Price
Quantity
SAFC
Cholesterol, Plant-Derived, SyntheChol®
SKU
Pack Size
Availability
Price
Quantity
Sigma-Aldrich
Atrasentan hydrochloride, ≥98% (HPLC)
SKU
Pack Size
Availability
Price
Quantity